ClinicalTrials.gg
RecruitingNCT04666961HORNEO01Updated Apr 22, 2022

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

A Phase 2 interventional study of Tamoxifen 20 mg and Anastrozole 1Mg Tab in Ductal Carcinoma in Situ, Extensive Disease and Mastectomy, sponsored by Institut Cancerologie de l'Ouest. Recruiting at 8 sites in France. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by Institut Cancerologie de l'Ouest · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
262
Allocation
Not applicable
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating — 4 open to participants now, 6 under way, 3 of them phase 3. Tamoxifen · Carcinoma, Intraductal, Noninfiltrating.

Planned enrollment
8th of 15
262 · median 262
Started
2021
the only one that year
Phase 2
7 of 16
3 open now
Registered
12th of 16
by date
Lead sponsor
1 of 16
Institut Cancerologie de l'Ouest

Among the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 12th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

4 of the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, or all of them as a file.
02

Study summary

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications.

This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients.

Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy.

Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence.

The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.

Read the detailed description

Description of the modalities for recruiting :

Following screening and discovery of a DCIS, patients are referred to the center for surgical management.

During a standard consultation, the surgeon presents the study to the patient who has been diagnosed with extensive DCIS with an indication for mastectomy. The surgeon provides the patient with the information note and the consent form to participate in the study. Once the consent form is signed by the patient and the investigator, the investigator prescribes a screening test to be performed within 30 days prior to the start of hormone therapy.

Screening assessment includes :

A clinical exam and a breast imaging exam (mammography and breast and axillary ultrasound). In case of a suspicious breast ultrasound image, microbiopsy will be performed to eliminate an infiltrating component.

One or more macrobiopsy. Each biopsied site will be located using an X-ray clip inserted at the time of sample.

A MRI post-macrobiopsy. Research of estrogen receptor expression

Once the investigator has verified and validated all the eligibility criteria, the patient will be included.

Prescriptions for Tamoxifen (non-menopausal patients) or Anastrozole (menopausal patients) are given to patients and dispensed by the center's pharmacy.

Monitoring during treatment :

Patients will benefit from imaging monitoring (Mammography, +/- breast ultrasound, +/- axillary ultrasound, MRI) at 3 months and 6 months during hormonotherapy.

In case of progression observed during treatment, hormone therapy will be stopped and you will then benefit from a mastectomy.

Surgery :

Mastectomy or tumorectomy will be performed according to the tumor response to hormone therapy observed on MRI.

All patients will benefit sentinel node detection. An additional axillary dissection will be performed based on the results of the sentinel node analysis.

Analysis of biomarkers and tumor microenvironment before and after treatment on diagnostic macrobiopsies and on tumorectomy or mastectomy will be performed at Institut de Cancérologie de l'Ouest.

Patients will be seen in postoperative consultation. Adjuvant treatments or re-surgical interventions will be prescribed, carried out, and the patients will be followed up and examined at 6 months after surgery or at the end of adjuvant treatments and then annually for 10 years (with control mammography).

Patients who have had conservative surgery will have an MRI at 6 months from the end of radiotherapy.

All patients will be asked to complete quality of life questionnaires at baseline, 6 and 12 months post-surgery, and annually for 9 years:

EORTC QLQ-C30 (up to 5 years only), Short Form (36) Health Survey questionnaire.

03

Conditions studied

  • Ductal Carcinoma in Situ
  • Extensive Disease
  • Mastectomy

Keywords

  • Neoadjuvant hormonotherapy
  • Tamoxifen
  • Anastrozole
  • conservative surgery
  • Breast cancer
  • extensive microcalcifications
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient ≥ 40 years old
  2. Histological diagnosis of ductal carcinoma in situ without infiltrating contingent
  3. Clinical T0N0
  4. Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status
  5. Indication for mastectomy
  6. DCIS visible on MRI performed with clip sequence
  7. Effective method for women of childbearing age who are sexually active and who have reported sexual activity.
  8. Informing the patient and obtaining free, informed and written consent signed by the patient and the investigator.
  9. Affiliated patient or beneficiary of the social security system.

Exclusion criteria

Exclusion Criteria:

  1. Invasive breast carcinoma
  2. Lobular carcinoma in situ
  3. pN+ patient
  4. Indication for conservative surgery
  5. to anastrozole or tamoxifen
  6. Concomitant treatments that may interact and reduce the efficacy of tamoxifen by interaction with cytochrome CYP2D6.
  7. proven multifocal lesion
  8. Contraindication to breast MRI (pace maker, heart valve, metallic implant, neuronal or peripheral stimulator, severe claustrophobia, ...)
  9. History of homolateral breast cancer
  10. Ongoing contralateral breast cancer
  11. Known mutation BRCA1 BRCA2
  12. Other cancer in progress at inclusion
  13. Pregnant woman, or breastfeeding,
  14. Persons deprived of liberty or under guardianship or trusteeship,
  15. Impossibility to undergo the medical follow-up of the trial for geographical, social, psychic or psychiatric reasons.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
262 participants (estimated)

Study arms

  • Experimental
    Extended ductal carcinoma in situ with mastectomy indication

    Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation. Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 : * Tamoxifen: box of tablets dosed at 20 mg * Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months. Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months.

    Drug: Tamoxifen 20 mg · Drug: Anastrozole 1Mg Tab

Interventions

  • DrugTamoxifenStudies of TamoxifenTamoxifen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.

  • DrugAnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.

06

What researchers measure

Primary outcomes

  1. Efficacy of neoadjuvant hormonotherapy

    % of conservative surgeries performed after hormonotherapy

    Time frame: 6 months of hormonotherapy

Secondary outcomes

  1. Disease-free survival (DFS)

    DFS rates at 5 and 10 years post-surgery

    Time frame: 5 and 10 years post-surgery

  2. Overall survival (OS)

    Survival rates at 5 and 10 years post-surgery

    Time frame: 5 and 10 years post-surgery

  3. Pathologic Complete Response (pCR)

    Pathologic complete response is defined as no residual invasive cancer in the surgical specimen

    Time frame: 6 months of hormonotherapy

  4. Predictive factors of response

    Response is defined by the variation in the diameter of the longest dimension of the target lesion measured by MRI

    Time frame: 3 and 6 months of hormonotherapy

  5. Quality of Life (Qol)

    EORTC QLQ-C30 questionnaire

    Time frame: At baseline, at 6 months and 12 months post-surgery, and then each year for 4 years

  6. Quality of Life (Qol)

    SF-36 questionnaire

    Time frame: At baseline, at 6 months and 12 months post-surgery, and then each year for 9 years

07

Study locations

7 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Aug 2024, 41 months after the start.

Of 36 phase 2 interventional studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 170. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 14, 2020
StartActual
Feb 3, 2021
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 1, 2033
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04666961
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Feb 3, 2021
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 1, 2033 (estimated)
Last update
Apr 22, 2022

Study contacts

Victoire BRILLAUD-MEFLAH, MD
Contact
Victoire.brillaud-meflah@ico.unicancer.fr
0240679818 ext. +33
Emilie DEBEAUPUIS
Contact
emilie.debeaupuis@ico.unicancer.fr
0240679844 ext. +33
Victoire BRILLAUD-MEFLAH, MD
principal investigator · Institut de Cancérologie de l'Ouest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamoxifen · Anastrozole

Start the discussion